Sone Capital Management LLC Invests $9.47 Million in Thermo Fisher Scientific Inc. (NYSE:TMO)

Sone Capital Management LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 18,196 shares of the medical research company's stock, valued at approximately $9,466,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Wedge Capital Management L L P NC grew its position in Thermo Fisher Scientific by 4.1% during the 4th quarter. Wedge Capital Management L L P NC now owns 706 shares of the medical research company's stock worth $367,000 after purchasing an additional 28 shares in the last quarter. Merit Financial Group LLC grew its holdings in shares of Thermo Fisher Scientific by 54.4% during the 4th quarter. Merit Financial Group LLC now owns 9,851 shares of the medical research company's stock valued at $5,125,000 after acquiring an additional 3,470 shares in the last quarter. Sanibel Captiva Trust Company Inc. grew its holdings in shares of Thermo Fisher Scientific by 5.4% during the 4th quarter. Sanibel Captiva Trust Company Inc. now owns 1,935 shares of the medical research company's stock valued at $1,007,000 after acquiring an additional 99 shares in the last quarter. HB Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 2.0% during the 4th quarter. HB Wealth Management LLC now owns 13,027 shares of the medical research company's stock valued at $6,777,000 after acquiring an additional 256 shares in the last quarter. Finally, Smith Salley Wealth Management grew its holdings in shares of Thermo Fisher Scientific by 13.9% during the 4th quarter. Smith Salley Wealth Management now owns 48,671 shares of the medical research company's stock valued at $25,320,000 after acquiring an additional 5,954 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Wall Street Analyst Weigh In

TMO has been the topic of several research analyst reports. Wells Fargo & Company lowered their price target on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Scotiabank reduced their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research note on Friday, April 25th. Royal Bank of Canada reduced their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Stifel Nicolaus reduced their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Finally, Citigroup reduced their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $607.43.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Price Performance

NYSE TMO traded up $1.85 on Thursday, reaching $400.13. The company's stock had a trading volume of 2,890,107 shares, compared to its average volume of 1,860,932. The firm has a market cap of $151.05 billion, a PE ratio of 24.21, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The business has a 50-day moving average price of $447.48 and a 200 day moving average price of $507.46. Thermo Fisher Scientific Inc. has a 52 week low of $390.50 and a 52 week high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company's quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.11 earnings per share. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a yield of 0.43%. Thermo Fisher Scientific's payout ratio is presently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.